Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 466 results for "fda centre for drug evaluation and re..."

FDA Grants Orphan Drug Designation to Aura Biosciences Novel T...

McGill University Health Centre researchers present pre-clinical in vivo data at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 21, 2015-- Aura Biosciences, a biotech ... Bloomberg, 3 days ago
[x]  

Nanoparticles in Biotechnology, Drug Development and Drug Delivery

/PRNewswire/ -- This BCC Research report provides detailed product analyses within health and wellness subsegments to overall industry trends in order to quantify and qualify the market for drug products for treating various disease conditions in ...
 Bloomberg5 days ago
[x]  

Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study

Abstract Objective To evaluate maternal medical and perinatal outcomes associated with antipsychotic drug use in pregnancy. Design High dimensional propensity score (HDPS) matched cohort study. Setting Multiple linked population health ...
 British Medical Journal1 week ago

Three Indian drug firms get US FDA marketing nod for generic aripiprazole

Three Indian pharmaceutical companies, namely Alembic Pharmaceuticals, Hetero Labs and Torrent Pharmaceuticals have received the US Food and Drug Administration (FDA) approval for generic versions of Abilify (aripiprazole), an atypical antipsychotic ...
 PharmaBiz3 weeks ago

ReNeuron Group has filed an Investigational New Drug (IND) application with the US FDA to commence a Phase I/II clinical trial with its human Retinal Progenitor Cell (hRPC)therapy candidate for retinitis pigmentosa (RP). RP is a group of hereditary diseas

ReNeuron Group has filed an Investigational New Drug (IND) application with the US FDA to commence a Phase I/II clinical trial with its human Retinal Progenitor Cell (hRPC)therapy candidate for retinitis pigmentosa (RP). RP is a group of ...
 Money Week1 month ago ReNeuron seeks to begin Phase 1/11 trials for hRPC  Stock Market Wire1 month ago ReNeuron seeks to begin Phase 1/11...  This is Money1 month ago
Global Research

FDA Colludes with Big Pharma to Cover Up Deaths in Psychiatric Drug Trials

Does the habitual use of antidepressants do more harm than good to many patients? Absolutely, says one expert in a new British Medical Journal report. Moreover, he says that the federal Food and Drug Administration might even be hiding the truth ...
 Global Research4 days ago
Medical Plastics News

Phillips-Medisize adds a human touch

During the development phases, pharma or medical device companies can encounter obstacles complying with the FDA's drug and medical device regulations, as well as other global regulations that determine which current good manufacturing practices ...
 Medical Plastics News1 month ago
European Pharmaceutical Review

Clovis Oncology receives Breakthrough Therapy designation for rucaparib for treatment of advanced ovarian cancer in patients with BRCA-mutated tumours

Clovis Oncology has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the Company's investigational agent rucaparib as monotherapy treatment of advanced ovarian cancer in patients who have ...
 European Pharmaceutical Review1 month ago

AstraZeneca to Update on Progress with Immuno-Oncology Pipeline and Combination Treatments at ASCO 2015

[May 13, 2015] AstraZeneca and MedImmune, the Company's global biologics research and development arm, will demonstrate rapid progress with their combination-focused oncology pipeline at the American Society of Clinical ...
 Green Technology1 week ago ASTRAZENECA : to Update on Progress with Immuno-Oncology Pipeline and Combination Treatments at ASCO 2015  4 Traders1 week ago
[x]  

Advaxis Announces First Patient Treated in Phase 1/2 Dose-Escalation Study of ADXS-HPV for Recurrent Cervical Cancer

The interventional, open-label, non-randomized dose-escalation study is designed to evaluate the safety, efficacy and immunological effect of ADXS-HPV administered at doses up to 1 x10 10 colony forming units (CFU) in repeat cycles of treatment in ...
 Morningstar.com2 months ago Advaxis, Inc. Announces First Patient Treated In Phase 1/2 Dose-Escalation Study Of ADXS-HPV For Recurrent Cervical Cancer  BioSpace2 months ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less